Cystatin C is downregulated in prostate cancer and modulates invasion of prostate cancer cells via MAPK/Erk and androgen receptor pathways.
about
Disruptive environmental chemicals and cellular mechanisms that confer resistance to cell deathuPAR and cathepsin B-mediated compartmentalization of JNK regulates the migration of glioma-initiating cellsIn vitro and in vivo prostate cancer metastasis and chemoresistance can be modulated by expression of either CD44 or CD147Identification of a myeloid-derived suppressor cell cystatin-like protein that inhibits metastasisPreoperative serum cystatin-C as a potential biomarker for prognosis of renal cell carcinoma.LncRNA Snhg1, a non-degradable sponge for miR-338, promotes expression of proto-oncogene CST3 in primary esophageal cancer cellsMicroRNAs of the mir-17~92 cluster regulate multiple aspects of pancreatic tumor development and progression.Cystatin C as a p53-inducible apoptotic mediator that regulates cathepsin L activityPrognostic value of cystatin C in patients with nasopharyngeal carcinoma: a retrospective study of 1063 patients.Clearance and beyond: the complementary roles of GFR measurement and injury biomarkers in acute kidney injury (AKI).Challenges facing early detection of acute kidney injury in the critically ill.Cystatin C is a disease-associated protein subject to multiple regulation.Bone Microenvironment Changes in Latexin Expression Promote Chemoresistance.Loss of the endothelial glycocalyx is associated with increased E-selectin mediated adhesion of lung tumour cells to the brain microvascular endothelium.Cryptotanshinone suppresses androgen receptor-mediated growth in androgen dependent and castration resistant prostate cancer cells.The selective inhibitory effect of a synthetic tanshinone derivative on prostate cancer cells.Pretreatment Serum Cystatin C Levels Predict Renal Function, but Not Tumor Characteristics, in Patients with Prostate Neoplasia.Detection of candidate biomarkers of prostate cancer progression in serum: a depletion-free 3D LC/MS quantitative proteomics pilot study.Cystatin C deficiency suppresses tumor growth in a breast cancer model through decreased proliferation of tumor cells.Grassystatins D-F, Potent Aspartic Protease Inhibitors from Marine Cyanobacteria as Potential Antimetastatic Agents Targeting Invasive Breast Cancer.Cystatin C as a predictor factor in patients with renal cell carcinoma treated by everolimus.Latexin regulates the abundance of multiple cellular proteins in hematopoietic stem cells.Utility of cystatin C as a potential bladder tumour biomarker confirmed by surface plasmon resonance technique.Serum Cystatin C Level Is Not a Promising Biomarker for Predicting Clinicopathological Characteristics of Bladder Urothelial Tumors.Cystatin A suppresses tumor cell growth through inhibiting epithelial to mesenchymal transition in human lung cancer.[Clinical significance of detection of cathepsin X and cystatin C in the sera of patients with lung cancer].Aberrant cystatin-C expression in blood from patients with breast cancer is a suitable marker for monitoring tumor burden
P2860
Q28080874-342CD752-723A-44C1-AE1F-757040429B49Q28237374-A0FCCC96-5F9B-4FFB-B557-55B76287D180Q28482047-058183B4-7050-4D77-81A5-D70A71D5A934Q28506334-ADB5B269-508E-42C0-BBAD-2F090B5B812EQ33769101-5C86FB20-BF3F-4775-9C88-154BCE9C44FEQ33829301-97E14FBC-21C1-4638-86DE-3F6B4E2111CDQ33829355-0A788D96-AC61-4088-BCDF-7829CCDA87F6Q36746295-62C22838-D410-43F0-8DD4-32B6BE367CB0Q37059721-C37985FF-1C03-4FA9-B6CC-C20B69F9DF3DQ37900798-FEF182B9-256C-4ADB-A1B6-D3942F669A72Q38271314-EFE5C414-C317-4539-A5D7-DFECD112D031Q38341202-D28E712D-AE55-4B06-92F6-91F91F3C70F3Q38721352-FBAE8A6F-DE7D-4031-A66A-BA9763DAF643Q38832390-7B7008F8-8504-413B-9092-5BCAAD5A171FQ39431280-B55308ED-5DBD-4AB4-90B2-6AB7D827EC35Q39471098-10A30A63-600C-4875-8892-C654DD9B068AQ41275437-E50C3498-4DFA-4612-ACF7-0CD24317D3CCQ41851428-770F9439-5C3D-4951-9812-4BA79F13B438Q46797867-2BC945F6-7904-4126-B1FC-422751A43218Q47583201-64097B7B-34DF-4B5C-92EA-CAD17A704A03Q50624187-3F73313A-F4A5-4113-BF89-3DB053FABADDQ51464227-F468B3A1-0489-49D5-AAEF-C5D10136BCCEQ55073013-C987D45C-A82C-406D-A2F3-4D9FA7A5103EQ55382081-F888089A-4242-4E8E-9953-08202AD44458Q55455492-9C43422E-4ADB-42E7-B40D-5B658CB9355FQ55465512-E5A639CE-5654-4B32-B7F6-2AFC3EC5379AQ57788837-37F632D4-9BF8-4487-B98B-15B53E6BB533
P2860
Cystatin C is downregulated in prostate cancer and modulates invasion of prostate cancer cells via MAPK/Erk and androgen receptor pathways.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Cystatin C is downregulated in ...... nd androgen receptor pathways.
@ast
Cystatin C is downregulated in ...... nd androgen receptor pathways.
@en
Cystatin C is downregulated in ...... nd androgen receptor pathways.
@nl
type
label
Cystatin C is downregulated in ...... nd androgen receptor pathways.
@ast
Cystatin C is downregulated in ...... nd androgen receptor pathways.
@en
Cystatin C is downregulated in ...... nd androgen receptor pathways.
@nl
prefLabel
Cystatin C is downregulated in ...... nd androgen receptor pathways.
@ast
Cystatin C is downregulated in ...... nd androgen receptor pathways.
@en
Cystatin C is downregulated in ...... nd androgen receptor pathways.
@nl
P2093
P2860
P1433
P1476
Cystatin C is downregulated in ...... nd androgen receptor pathways.
@en
P2093
Anders Bjartell
Barbara Wegiel
Jenny Liao Persson
Leszek Helczynski
Magnus Abrahamson
Thomas Jiborn
P2860
P356
10.1371/JOURNAL.PONE.0007953
P407
P577
2009-11-23T00:00:00Z